Immunome
IMNM
29 hedge funds and large institutions have $10.2M invested in Immunome in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.
47% more call options, than puts
Call options by funds: $240K | Put options by funds: $163K
0.8% less ownership
Funds ownership: 23.07% → 22.27% (-0.8%)
3% less funds holding
Funds holding: 30 → 29 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
72% less capital invested
Capital invested by funds: $36.4M → $10.2M (-$26.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
IMNM Hedge Fund Activity: Q1 2022 in Review
29 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2022, worth a combined $10.2M — down 72% from $36.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IMNM and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 6 added.
The largest buyer was Baldwin Investment Management, opening a new position worth an estimated $190K. The largest seller was Morgan Stanley, cutting an estimated $486K.
- 29 institutional investors held Immunome (IMNM) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $10.2M of Immunome stock for Q1 2022, down 72% quarter-over-quarter.
- 3 funds opened new Immunome positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Immunome buyer in Q1 2022 was Baldwin Investment Management, an estimated $190K added.
- The largest Immunome seller in Q1 2022 was Morgan Stanley, an estimated $486K sold.
Based on aggregated 13F filings for Q1 2022.